Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

18F meta fluorobenzylguanidine - Illumina Radiopharmaceuticals

Next Previous
X
Search
Drug Profile

18F meta fluorobenzylguanidine - Illumina Radiopharmaceuticals

Alternative Names: 18F-meta-fluorobenzylguanidine - Illumina Radiopharmaceuticals; 18F-mFBG; 18F-mFBG - Illumina Radiopharmaceuticals; Florbenguane F-18; IRP101; Meta-fluorobenzylguanidine - Illumina Radiopharmaceuticals

Latest Information Update: 16 Feb 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Illumina Radiopharmaceuticals
  • Class Contrast media; Diagnostic agents; Fluorobenzenes; Guanidines; Imaging agents; Radiopharmaceutical diagnostics; Small molecules
  • Mechanism of Action Emission-computed tomography enhancers; Magnetic resonance imaging enhancers; Positron-emission tomography enhancers; Radionuclide imaging enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Neuroblastoma
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Cardiovascular disorders; Neuroblastoma

Most Recent Events

  • 16 Feb 2024 Innervate Radiopharmaceuticals plans a phase II trial for Neuroblastoma, Pheochromocytoma and Paraganglioma in USA in July 2024 (NCT06233903)
  • 05 Feb 2021 Chemical structure information added
  • 26 Jan 2021 Preclinical trials in Neuroblastoma (Diagnosis) in USA (unspecified route) before January 2021 (NCT04724369)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top